abstract |
The invention relates to pharmaceutical compositions for the prevention and / or treatment of pathological processes involving the induction of TNF-alpha secretion comprising a pharmaceutically acceptable vehicle and low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, low molecular weight heparin is present in a low dose and is administered at intervals of about 5-8 days. In addition, low molecular weight heparin can inhibit TNF-alpha secretion in vitro by resting T cells and / or macrophages in response to T cell specific antigens, mitogens, macrophage activators, ruptured extracellular matrix ( dECM), laminin, fibronectin, and others. |